Compare Stocks

→ Biden’s $374B Giveaway Into This Sector (From DTI) (Ad)

Compare stocks and their fundamentals, performance, price, and technicals. Use this free stock comparison tool to evaluate companies based on their analyst ratings, book value, debt, dividend, MarketRank, news sentiment, price performance, profitability, and more. Enter up to ten stock symbols separated by a comma or space (ex. BAC, JPM, WFC, C, GS).

Comparative Price Performance Over Time

Compare Stocks - Price & Volume

Company	Current Price	50-Day Moving Average	52-Week Range	Market Cap	Beta	Avg. Volume	Today's Volume
PTX Pernix Therapeutics		$0.16	$0.20 ▼ $3.30	$419K	1.2	3.04 million shs	16,105 shs
QPT AdvisorShares Q Portfolio Blended Allocation ETF	$19.10 +0.1%	$19.10	$18.63 ▼ $27.54	$1.91M	N/A	1,912 shs	19,400 shs
SBTX Silverback Therapeutics	$9.06 -1.3%	$8.64	$2.80 ▼ $8.97	$326.69M	0.6	337,931 shs	456,563 shs

10 Best Stocks to Own in 2024

Click the link below and we'll send you MarketBeat's list of the 10 best stocks to own in 2024 and why they should be in your portfolio.

Get This Free Report

Price Performance

Company	1-Day Performance	7-Day Performance	30-Day Performance	90-Day Performance	1-Year Performance
PTX Pernix Therapeutics	0.00%	0.00%	0.00%	0.00%	0.00%
QPT AdvisorShares Q Portfolio Blended Allocation ETF	0.00%	0.00%	0.00%	0.00%	0.00%
SBTX Silverback Therapeutics	-1.31%	-2.89%	-0.66%	+49.01%	+32.07%

Biden’s $374B Giveaway Into This Sector (Ad)

Biden’s Climate Bill Could Send Your Retirement Accounts Soaring – Or Diving See what this $374B giveaway could mean for your retirement right here

Click here for the full story

MarketRank™

Company	Overall Score	Analyst's Opinion	Short Interest Score	Dividend Strength	ESG Score	News and Social Media Sentiment	Company Ownership	Earnings & Valuation
PTX Pernix Therapeutics	N/A	N/A	N/A	N/A	N/A	N/A	N/A	N/A
QPT AdvisorShares Q Portfolio Blended Allocation ETF	N/A	N/A	N/A	N/A	N/A	N/A	N/A	N/A
SBTX Silverback Therapeutics	N/A	N/A	N/A	N/A	N/A	N/A	N/A	N/A

Analyst Ratings

Company	Consensus Rating Score	Consensus Rating	Consensus Price Target	% Upside from Current Price
PTX Pernix Therapeutics	N/A	N/A	N/A	N/A
QPT AdvisorShares Q Portfolio Blended Allocation ETF	0.00	N/A	N/A	N/A
SBTX Silverback Therapeutics	N/A	N/A	N/A	N/A

Sales & Book Value

Company	Annual Revenue	Price/Sales	Cashflow	Price/Cash	Book Value	Price/Book
PTX Pernix Therapeutics	$146.07M	0.00	N/A	N/A	($14.77) per share	0.00
QPT AdvisorShares Q Portfolio Blended Allocation ETF	N/A	N/A	N/A	N/A	N/A	N/A
SBTX Silverback Therapeutics	N/A	N/A	N/A	N/A	$7.41 per share	N/A

Profitability & Earnings

Company	Net Income	EPS	Trailing P/E Ratio	Forward P/E Ratio	P/E Growth	Net Margins	Return on Equity (ROE)	Return on Assets (ROA)	Next Earnings Date
PTX Pernix Therapeutics	-$77.14M	N/A	0.00	N/A	N/A	-59.70%	N/A	-37.01%	N/A
QPT AdvisorShares Q Portfolio Blended Allocation ETF	N/A	N/A	0.00	∞	N/A	N/A	N/A	N/A	N/A
SBTX Silverback Therapeutics	-$89.48M	-$2.42	N/A	∞	N/A	N/A	-29.62%	-28.20%	N/A

Dividends

Company	Annual Payout	Dividend Yield	3-Year Dividend Growth	Payout Ratio	Years of Consecutive Growth
PTX Pernix Therapeutics	N/A	N/A	N/A	N/A	N/A
QPT AdvisorShares Q Portfolio Blended Allocation ETF	$0.08	0.42%	N/A	N/A	N/A
SBTX Silverback Therapeutics	N/A	N/A	N/A	N/A	N/A

Debt

Company	Debt-to-Equity Ratio	Current Ratio	Quick Ratio
PTX Pernix Therapeutics	N/A	1.08	0.92
QPT AdvisorShares Q Portfolio Blended Allocation ETF	N/A	N/A	N/A
SBTX Silverback Therapeutics	N/A	67.87	67.87

Ownership

Institutional Ownership

Company	Institutional Ownership
PTX Pernix Therapeutics	20.43%
QPT AdvisorShares Q Portfolio Blended Allocation ETF	N/A
SBTX Silverback Therapeutics	74.89%

Insider Ownership

Company	Insider Ownership
PTX Pernix Therapeutics	1.30%
QPT AdvisorShares Q Portfolio Blended Allocation ETF	N/A
SBTX Silverback Therapeutics	34.40%

Miscellaneous

Company	Employees	Shares Outstanding	Free Float	Optionable
PTX Pernix Therapeutics	N/A	14.51 million	N/A	Optionable
QPT AdvisorShares Q Portfolio Blended Allocation ETF	N/A	100,000	N/A	Not Optionable
SBTX Silverback Therapeutics	83	36.06 million	23.65 million	Not Optionable

C4XD, IMC, PTX, QPT, and SBTX Headlines

Source	Headline
	Silverback Therapeutics (NASDAQ:SBTX) Trading Down 2% marketbeat.com - April 3 at 2:15 AM
	ARS Pharmaceuticals Inc (SPRY) uk.investing.com - May 11 at 1:32 PM
	Wild Isles wwf.org.uk - March 12 at 9:31 AM
	A look back at RNA Therapeutics – day one pharmaphorum.com - February 24 at 12:35 AM
	SPRY ARS Pharmaceuticals, Inc. seekingalpha.com - January 24 at 8:04 PM
	ARS Pharma CEO Richard Lowenthal Holds 8% Silverback Stake After Merger 247wallst.com - November 22 at 6:29 AM
	Dr. Sarina Tanimoto Discloses Position in SBTX / Silverback Therapeutics nasdaq.com - November 18 at 8:19 PM
	ARS Pharmaceuticals Announces Presentation of Clinical Data Supporting neffy® (epinephrine nasal spray) for the Treatment of Allergic Reactions (Type I) including Anaphylaxis finance.yahoo.com - November 10 at 6:41 PM
	ARS Pharmaceuticals Closes Merger with Silverback Therapeutics finance.yahoo.com - November 8 at 5:59 PM
	Silverback : FDA Accepts ARS Pharm's NDA For Neffy For Treatment Of Allergic Reactions markets.businessinsider.com - October 28 at 8:15 AM
	FDA accepts ARS Pharma’s NDA for Neffy thepharmaletter.com - October 24 at 10:29 AM
	SHAREHOLDER INVESTIGATION: Halper Sadeh LLC Investigates HIL, SBTX, COWN, AERI kentuckytoday.com - October 23 at 7:22 PM
	Silverback Therapeutics, Inc. announces the FDA’s acceptance of ARS Pharmaceuticals’ NDA for neffy® (epinephrine nasal spray) for the Treatment of Allergic Reactions (type I) including Anaphylaxis finance.yahoo.com - October 21 at 7:59 AM
	Is Silverback Therapeutics Inc (SBTX) Stock a Good Investment? aaii.com - October 19 at 11:52 AM
	SHAREHOLDER ALERT: The M&A Class Action Firm is Investigating the Merger – RFP, SBTX, AAWW, COWN bakersfield.com - October 12 at 11:07 PM
	INVESTIGATION ALERT: Halper Sadeh LLC Investigates CVET, SBTX, IRBT markets.businessinsider.com - September 17 at 5:10 AM
	SBTX Silverback Therapeutics, Inc. seekingalpha.com - September 15 at 10:58 PM
	SHAREHOLDER NOTICE: Halper Sadeh LLP Investigates FTAI, SBTX, CVET, GBT markets.businessinsider.com - September 6 at 11:53 AM
	SHAREHOLDER INVESTIGATION NOTICE: Halper Sadeh LLP Investigates HNGR, SBTX, IEA, ZY markets.businessinsider.com - August 23 at 6:32 PM
	SHAREHOLDER INVESTIGATION NOTICE: Halper Sadeh LLP Investigates VIVO, HNGR, SBTX apnews.com - August 17 at 12:02 PM
	SHAREHOLDER INVESTIGATION NOTICE: Halper Sadeh LLP Investigates IEA, BBQ, SBTX apnews.com - August 11 at 1:33 AM
	SHAREHOLDER ALERT: Weiss Law Reminds SBTX, LJPC, CNVY, and DRE Shareholders About Its Ongoing Investigations morningstar.com - July 30 at 7:00 AM
	INVESTIGATION ALERT: Halper Sadeh LLP Investigates HNGR, SBTX, IEA, ZY apnews.com - July 28 at 2:21 AM
	Shareholder Alert - The M&A Class Action Firm Announces the Investigation of Silverback Therapeutics, Inc. - SBTX benzinga.com - July 27 at 9:21 PM

Media Sentiment Over Time

Company Descriptions

Pernix Therapeutics

NASDAQ:PTX

Pernix Therapeutics Holdings, Inc., a specialty pharmaceutical company, focuses on the acquisition, development, and commercialization of prescription drugs primarily for the United States market. It targets underserved therapeutic areas, such as central nervous system (CNS), including pain, neurology, and psychiatry. The company's products comprise Zohydro ER with BeadTek, an opioid agonist indicated for the management of pain; Silenor, a non-narcotic, non-scheduled, and non-addictive prescription sleep aid for the treatment of insomnia characterized by difficulty with sleep maintenance; and Treximet, a fixed dose combination product indicated for the treatment of acute migraine. Pernix Therapeutics Holdings, Inc. markets and sells its non-core products, including generics through its wholly owned subsidiaries; and markets its non-promoted products through distributors and trade partners. It serves drug wholesalers, specialty pharmacies, retail drug stores, mass merchandisers, and grocery store pharmacies. Pernix Therapeutics Holdings, Inc. was founded in 1996 and is headquartered in Morristown, New Jersey.

AdvisorShares Q Portfolio Blended Allocation ETF

NYSEARCA:QPT

Silverback Therapeutics

NASDAQ:SBTX

Silverback Therapeutics, Inc., a biopharmaceutical company, develops tissue-targeted therapeutics for the treatment of chronic viral infections, cancer, and other serious diseases. The company offers SBT8230 to treat chronic hepatitis B virus infection by eliciting an anti-viral immune response by targeting TLR8 activation to the liver. Silverback Therapeutics, Inc. was incorporated in 2016 and is headquartered in Seattle, Washington.

Get 30 Days of MarketBeat All Access Free

Best-in-Class Portfolio Monitoring
View the latest news, buy/sell ratings, SEC filings and insider transactions for your stocks. Compare your portfolio performance to leading indices and get personalized stock ideas based on your portfolio.
Stock Ideas and Recommendations
Get daily stock ideas from top-performing Wall Street analysts. Get short term trading ideas from the MarketBeat Idea Engine. View which stocks are hot on social media with MarketBeat's trending stocks report.
Advanced Stock Screeners and Research Tools
Identify stocks that meet your criteria using seven unique stock screeners. See what's happening in the market right now with MarketBeat's real-time news feed. Export data to Excel for your own analysis.

Start Your 30-Day Free Trial